Oncolytics Biotech Inc. has announced updated data from its GOBLET study, demonstrating significant efficacy for its treatment, pelareorep, in patients with second-line squamous cell anal cancer. The results indicate a median duration of response of approximately 15 months, which surpasses historical benchmarks for existing treatments. This development is crucial as it positions Oncolytics to potentially expand its applications into other HPV-driven cancers.

The GOBLET study evaluates pelareorep in combination with atezolizumab, a checkpoint inhibitor, in treating patients with advanced anal cancer. Notably, all patients who responded to the treatment survived beyond 12 months, with some exceeding 24 months. These findings could pave the way for regulatory advancements, including potential accelerated approval pathways from the FDA.

Background

Oncolytics Biotech Inc., based in San Diego, California, operates within the pharmaceutical preparations sector (SIC: 2834). The company is publicly traded on the Nasdaq under the ticker ONCY. As a clinical-stage immunotherapy company, Oncolytics is focused on developing innovative treatments for cancer, particularly through its proprietary oncolytic virus platform.

What the Filing Says

According to the recent filing, Oncolytics Biotech issued a press release on October 27, 2026, detailing the updated data from Cohort 4 of the GOBLET study. The filing states, “The median duration of response is approximately 15 months, which compares favorably with historical results.” It also highlights that 100% of the responding patients survived for over one year.

Impact

This announcement is likely to impact patients suffering from squamous cell anal cancer, as well as those with HPV-related cancers. The positive results may also influence healthcare providers and payers, as they consider the efficacy and potential benefits of incorporating pelareorep into treatment regimens. Furthermore, the findings could affect competitors in the pharmaceutical industry, which may feel pressured to enhance their own treatment offerings in response to Oncolytics' promising data.

What's Next

Oncolytics plans to pursue further clinical studies and explore partnerships to support the registrational development of pelareorep in anal cancer. The filing does not specify what happens next, but the company is optimistic about expanding its research into other HPV-associated tumors, including head and neck cancer.